Renaissance Capital logo

Autolus Therapeutics Priced, Nasdaq: AUTL

Developing blood cancer therapies based on highly targeted CAR T cells.

Industry: Health Care

First Day Return: +47.1%

Industry: Health Care

We are a biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer. Using our broad suite of proprietary and modular T cell programming technologies, we are engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. We believe our programmed T cell therapies have the potential to be best-in-class and offer cancer patients substantial benefits over the existing standard of care, including the potential for cure in some patients. Our clinical-stage pipeline comprises five programs being developed in six hematological and solid tumor indications. We expect to complete the proof-of-concept phases of four Phase 1/2 clinical trials in hematological cancer indications by early 2019. These clinical programs are adaptive and designed to allow collection of sufficient data in the expansion phase of the trials to potentially support registration. We have worldwide commercial rights to all of our programmed T cell therapies.
more less
IPO Data
IPO File Date 05/07/2018
Offer Price $17.00
Price Range $15.00 - $17.00
Offer Shares (mm) 8.8
Deal Size ($mm) $150
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 06/21/2018
Offer Price IPO Intelligence Only
Price Range IPO Intelligence Only
Offer Shares (mm) IPO Intelligence Only
Deal Size ($mm) $150
Lock-Up Date IPO Intelligence Only
Street Research IPO Intelligence Only
Underwriters
IPO Intelligence Only
Company Data
Headquarters London, United Kingdom
Founded 2014
Employees at IPO 126
Website www.autolus.com

Autolus Therapeutics (AUTL) Performance